Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Ticker SymbolBBLG
Company nameBone Biologics Corp
IPO dateNov 27, 2015
Founded at2007
CEOMr. Jeffrey Frelick
Number of employees2
Security typeOrdinary Share
Fiscal year-endNov 27
Address2 Burlington Woods Dr Ste 100
CityBURLINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01803-4551
Phone17815524452
Websitehttps://www.bonebiologics.com/
Ticker SymbolBBLG
IPO dateNov 27, 2015
Founded at2007
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data